LAS VEGAS, NV, March 13 /PRNewswire-FirstCall/ - Neuroscience Therapy Corp. unveiled today its leading product: P-Stim(TM) Electro Stimulation Device.
P-Stim is a unique miniaturized electro stimulation device, which utilizes modern day microchip technology and traditional acupuncture techniques. It is designed to treat pain over a period of several days while allowing the patient complete comfort and mobility.
Since 2000, P-Stim has been demonstrated to be safe and effective for treating a number of acute and chronic pain conditions. Commercially launched outside the U.S. in late 2002, P-Stim has been used to treat approximately 7,500 patients. P-Stim is currently being administered by physicians in Europe.
P-Stim has been proven to be safe and effective in Europe for treating a number of conditions. One of the major strengths of P-Stim is, unlike many pharmaceutical pain killers, P-Stim has no known side effects.
With the neurostimulation industry in its infancy and billions of dollars being spent each year on pain related conditions, Neuroscience Therapy Corporation plans to prosper in this thriving market.
About Neuroscience Therapy Corporation:
Neuroscience Therapy Corporation’s operations are located in Southern California. It holds the rights to a new, safe and innovative technology to relieve pain. Its product portfolio consists of two complimentary products: the P-Stim(TM) Electro Stimulation Device and the Multi-Point(TM) Stylus. These products have no known side effects, unlike many pharmaceutical pain relievers. The neurostimulation market is in its infancy and could reach several billion dollars in sales. The Company is working toward being a leader in this market. For more information about Neuroscience Therapy Corp., visit: www.neurosciencetherapy.com.
Legal Notice Regarding Forward Looking Statements
The statements in this press release that relate to the Company’s expectations with regard to the future impact on the Company’s results are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results.
Contact: Neuroscience Therapy Corporation Raymond Johnson 1-866-639-3900
Neuroscience Therapy Corp.
CONTACT: Neuroscience Therapy Corporation, Raymond Johnson, 1-866-639-3900
